Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

NCT04035005 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Effects of Ocrevus in Relapsing Multiple Sclerosis

NCT04387734 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

NCT07299019 ·Status: RECRUITING ·Phase: PHASE3

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

NCT04377555 ·Status: COMPLETED ·Phase: PHASE4

Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation

NCT04230174 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

NCT03523858 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)

NCT03606460 ·Status: COMPLETED ·Phase: PHASE3

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02861014 ·Status: COMPLETED ·Phase: PHASE3

Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

NCT03157830 ·Status: COMPLETED

Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714

NCT03691077 ·Status: UNKNOWN ·Phase: PHASE3

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

NCT02688985 ·Status: COMPLETED ·Phase: PHASE3

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

NCT06677710 ·Status: SUSPENDED ·Phase: PHASE1

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02637856 ·Status: COMPLETED ·Phase: PHASE3

A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting

NCT03589105 ·Status: COMPLETED ·Phase: PHASE4

A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

NCT04711148 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

NCT02807285 ·Status: NO_LONGER_AVAILABLE

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

NCT05285891 ·Status: RECRUITING ·Phase: PHASE4

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

NCT03085810 ·Status: TERMINATED ·Phase: PHASE3

Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

NCT04855617 ·Status: COMPLETED

Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

NCT03593590 ·Status: COMPLETED

Ocrelizumab Effects on the Metabolome in MS

NCT03873389 ·Status: COMPLETED

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

NCT04261790 ·Status: COMPLETED ·Phase: PHASE4

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00676715 ·Status: COMPLETED ·Phase: PHASE2

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

NCT07207148 ·Status: RECRUITING

Ocrelizumab Access by Socio-Economic Status

NCT05131984 ·Status: COMPLETED